Plain-English translation of NCT07330596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a new drug called QL1706, when combined with standard , can help people with advanced lung cancer whose tumors have stopped responding to previous immunotherapy treatments. Half of the participants will receive QL1706 plus (either gemcitabine or docetaxel), while the other half will receive alone. Researchers want to see if adding this new medication improves treatment outcomes.
Many people with advanced lung cancer eventually stop responding to standard immunotherapy treatments, leaving them with limited options. This medication is being studied to see if it can help patients whose cancer has progressed despite previous immunotherapy, offering a new path forward when current treatments stop working.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication (QL1706) combined with or alone. The medication is given as an intravenous infusion, and you will receive your assigned treatment on a set schedule over multiple visits. Throughout the study, your doctors will monitor you with blood tests and scans to see how your cancer is responding and watch for any side effects.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
China